<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> accounts for 90% of <z:mp ids='MP_0002055'>diabetes</z:mp> cases and is associated with macro- and microvascular complications of high morbidity and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Individuals with increased risk for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> include those with impaired fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> (IFG), <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT), and especially those with combined IFG and IGT </plain></SENT>
<SENT sid="2" pm="."><plain>These individuals are part of a group known as <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>Approximately 25% of individuals with <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e> will develop type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in three to five years </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0003074'>Hyperglycemia</z:hpo>, in the absence of <z:mp ids='MP_0002055'>diabetes</z:mp>, is also associated with increased risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Studies have shown that changes in lifestyle and drug interventions are effective in delaying or preventing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in patients with <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> is the drug of choice when medical treatment is warranted </plain></SENT>
<SENT sid="7" pm="."><plain>IGT and IFG are associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and, despite controversy, most studies reinforce the importance of these conditions in the development of micro- and macrovascular disease </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, therapeutic interventions in patients with <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e> are important in primary prevention of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and its <z:hpo ids='HP_0011010'>chronic</z:hpo> complications </plain></SENT>
</text></document>